Consolidated sales of the Ceva Group reached â‚¬546m at the end of June 2017, representing growth of 20% versus last year and +6.6% at constant perimeter and exchange rates.
Consolidated sales of the Ceva Group reached €546m at the end of June 2017, representing growth of 20% versus last year and +6.6% at constant perimeter and exchange rates.
Sales grew across all zones despite significant negative currency impact, especially in the Africa, Middle East, Eastern Europe, Russia and Turkey Zone which grew by 14% (at constant currency and perimeter), with strong overall performance in Latin America (+87%), Asia (+40%), North America Pacific (+13%) and Europe (+10%).
All species are growing, especially Swine (+45%) and Ruminant (+36%) reinforced by acquisitions, with Poultry (+11%) and Companion Animal (+16%) also posting significant organic growth.
The group delivered an operational result ahead of its budgeted objective and continued to make significant investments in R&D and production sites around the world.
Dr. Marc Prikazsky, Ceva’s Chairman and CEO said, “This is a very positive start to the year, continuing our trend of double-digit growth. Thanks to the contributions of our new colleagues in the businesses recently acquired and the extraordinary commitment of all Ceva employees, we were once again able to outperform the average growth in the animal health sector.”
About Ceva Santé Animale:
Ceva Santé Animale was founded in 1999 and is a global veterinary health company, focused on research, development, production and marketing of pharmaceutical products and vaccines for companion animals, livestock, swine and poultry. Its headquarters are in Libourne (Gironde).
Ceva Chairman and CEO is Marc Prikazsky.